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Abstract
West Nile virus (WNV) has caused outbreaks and sporadic infections in Central, Eastern and Mediterranean Europe
for over 45 years. Most strains responsible for the European and Mediterranean basin outbreaks are classified as
lineage 1. In recent years, WNV strains belonging to lineage 1 and 2 have been causing outbreaks of neuroinvasive
disease in humans in countries such as Italy, Hungary and Greece, while mass mortality among birds was not
reported. This study characterizes three European strains of WNV isolated in Italy (FIN and Ita09) and Hungary
(578/10) in terms of in vitro replication kinetics on neuroblastoma cells, LD50 values in C57BL/6 mice, median day
mortality, cumulative mortality, concentration of virus in the brain and spinal cord, and the response to infection in the
brain. Overall, the results indicate that strains circulating in Europe belonging to both lineage 1 and 2 are highly
virulent and that Ita09 and 578/10 are more neurovirulent compared to the FIN strain.
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Introduction
West Nile virus (WNV) is a positive-sense single-stranded
RNA virus, which belongs to the genus Flavivirus. WNV is
transmitted by infected mosquitoes and is maintained in an
enzootic cycle between mosquitoes and birds, but can also
infect and cause disease in horses and humans, which serve
as incidental dead-end hosts. Previously, WNV was considered
an Old World virus being endemic in parts of Africa, Europe,
the Middle East, and Asia [1]. However, in 1999, WNV
emerged in New York City in the United States and has since
rapidly spread across North America, Mexico, South America,
and the Caribbean [2-4]. No vaccines or specific therapy are
currently registered for use in humans.
WNV has caused sporadic outbreaks in Central, Eastern and
Mediterranean Europe for over 45 years. Phylogenetically
WNV strains are classified into two major lineages. Lineage 1
constitutes strains from North America, Africa, the Middle East,
Asia, Australia (Kunjin virus) and Europe. Lineage 2 strains
were restricted to sub-Saharan Africa. This genetic
classification has been used frequently to classify WNV
obtained during outbreaks. In this respect, many strains
isolated from patients with neuroinvasive disease have been
classified as lineage 1. In 2008, an outbreak affected small
numbers of wild birds, horses and humans in eight provinces in
three regions of Italy [5,6]. Subsequently, in 2009, a new
epidemic was reported in the same region, as well as in other
neighboring regions in Italy, with up to 17 confirmed cases of
WNV neuroinvasive disease [7]. Several strains of WNV were
isolated from human specimens and sequenced. Phylogenetic
analyses on the basis of the E and NS3/NS5 revealed that
these strains belong to lineage 1, clade 1a, and constitute a
distinct group within the western Mediterranean cluster [8]. In
2004, a lineage 2 strain was isolated from birds of prey in
Hungary [9], which established itself in the region and largely
spread throughout the country and into eastern Austria by 2008
[10]. During this outbreak, cases of human neuroinvasive
disease were comparatively rare and rather mild with no deaths
reported [10]. Recently, Greece became the focus of a large
outbreak in summer-autumn 2010 [11]. Up to October 4th,
2010, 192 cases of neuroinvasive disease in humans, including
32 deaths, had been laboratory diagnosed, all in the elderly.
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Culex pipiens mosquitoes trapped in Nea Santa were found to
be positive for WNV RNA, and sequencing of the NS5 gene
gave the first indication that this virus belongs to lineage 2, and
that it is highly similar to the strain that emerged in Hungary in
2004 [10]. As of November 2012, 237 confirmed human cases
have been reported in the European Union (EU), of which 161
cases were in Greece, 50 in Italy, 14 in Romania and 12 in
Hungary (http://www.ecdc.europa.eu/en/healthtopics/
west_nile_fever/West-Nile-fever-maps/Pages/index.aspx).
These outbreaks were caused by both lineage 1 and 2 strains
of WNV.
It is remarkable that many of the outbreaks in humans
caused by lineage 1 and 2 were not preceded by massive bird
mortality. WNV-induced wild bird mortality has been described
in Europe but much less intensively compared to the US. The
outbreak in 1998 in Israel and 1999 in New York were the first
ones where mortality among birds was reported. Because of
the higher incidence of WNV neuroinvasive disease seen
during the US outbreak, it was hypothesized that the
introduced strain was more virulent. The complete genomic
sequencing of the bird and human virulent IS-98 and NY99
strains of WNV revealed that both isolates belong to the same
phylogenetic clade, sharing more than 99.8% nucleotide
similarity [12]. We wished to characterize and determine the
virulence profile of the European-derived WNV strains.
Virulence for WNV has often been associated with envelope
(E) protein glycosylation [13] and glycosylation of the NS1
protein [14]. Other virulence factors described for WNV include
tropism, induction of rapid cell death, resistance to interferon,
quasispecies generation and up-regulation of MHC class I
expression [15]. It is therefore clear that virulence is a multi-
factorial process and that many aspects need to be studied in
order to elucidate the pathogenic force of viruses. Several
parameters can be used to describe virulence. In vivo
surrogate markers of virulence include immune-interfering
properties, lethal dose 50 (LD50), median survival time (ST50),
tropism for particular cells or tissues, as well as the viral burden
present in infected tissues. In the present study we
characterized the virulence of three selected European strains
of WNV in vitro and also in vivo by infection of C57BL/6 mice
with different doses of these virus strains. We compared their
LD50, ST50, cell tropism and pathology in the brain, as well as
the response to infection in the brain.
Materials and Methods
Ethics statement
All animal experiments described in this paper have been
conducted according to Dutch guidelines for animal
experimentation and approved by the Animal Welfare
Committee of the Erasmus Medical Center, Rotterdam, The
Netherlands. All efforts were made to minimize animal
suffering. The Dutch Animal Experimentation Act (1977)
demands that research establishments request a license from
the Ministry of Welfare, Public Health and Cultural Affairs
before carrying out any experiment. Research plans must be
approved by local ethical review committees that consider the
benefit of an experiment and whether this justifies the distress
caused to the animals used in the procedure. The pain
assessment is prospective and a system of research plan
review based on the cost-benefit principle is also in place. A
statistical reporting system of all animal experimentation
provides the opportunity to count the number of experiments
involving pain or distress to the animals with or without pain
relief drugs.
Cells and viruses
Vero E6 cells were cultured in DMEM with 10% heat-
inactivated fetal bovine serum (HI-FBS), supplemented with
0.75% sodium bicarbonate and 10 mM hepes buffer. C6/36
insect cells were cultured in Leibovitz-15 medium
supplemented with 5% HI-FBS, 10% tryptose phosphate broth,
0.75% sodium bicarbonate and 10 mM hepes buffer. All media
were supplemented with antibiotics (100 U penicillin, 100 µg/ml
streptomycin) and 2 mM L-glutamine. Cell culture reagents
were obtained from LONZA (Lonza Benelux BV, Breda, the
Netherlands). All cell lines tested negative for mycoplasma
using a PCR assay as described [16]. Viruses used in this
study and passage history were as follows: two lineage 1
Italian strains, FIN (a kind gift from Dr. Vittorio Sambri,
University of Bologna, Italy; P2 on Vero E6) and Ita09
(accession GU011992.2, kindly provided by Dr. Louisa Barzon,
University of Padova, Italy; P1 on Vero E6) and the Hungarian
lineage 2 strain 578/10 (accession KC496015, a kind gift from
Dr. Tamás Bakonyi, Szent István University, Hungary; P2 on
Vero E6) isolated from the brain of a horse that died of WNV-
neuroinvasive disease. Virus stocks used for this study were
prepared by growing the viruses once on C6/36 insect cells
and viral titers were determined on Vero E6 cells using the
Spearman & Kärber method [17,18] after determining
cytopathic effects five days post inoculation.
Sequencing of the envelope gene of WNV strains
Viral RNA was isolated from C6/36 derived viral stocks using
the MagnaPure LC robot system and the Total Nucleic acid
isolation kit according to the manufacturer’s instructions
(Roche, Almere, The Netherlands). Primers specific for the E
protein were designed using the Primer Select module of
DNASTAR software (DNASTAR, Madison WI, USA) and
adjusted manually to obtain highest similarity with NY99 (Table
S1). cDNA was synthesized using specific primers and
Superscript III RT enzyme (Invitrogen, Breda, The Netherlands)
and subsequently PCR-amplified using Taq DNA polymerase
(Invitrogen) according to the instructions of the manufacturer.
DNA fragments were gel-purified and cloned into the pCR4-
TOPO vector (Invitrogen). The cloning reaction products were
transformed into E. coli (One-Shot Top 10 competent cells;
Invitrogen). Positive transformed bacteria were identified by
PCR using M13 primers and sequenced using specific primers
(Table S1). Five bacterial clones were selected to determine
the consensus sequence of the virus stocks. Sequencing was
performed in an ABI3130XL sequencer using ABI PRISM Big
Dye® Terminator (Applied Biosystems, Bleiswijk, The
Netherlands). Sequences were analyzed using the SeqMan
module of DNASTAR software and aligned to a reference
strain (original sequence of isolate deposited in GenBank) so
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that the E protein of the different strains was obtained from the
consensus sequence of five bacterial colonies. The GenBank
sequence for the original FIN isolate had not yet been
deposited; therefore a closely related Italian (JF719067)
sequence that gave at least 99% identity in BLAST was used
as a reference instead.
Sequencing the complete genome of WNV-FIN
RNA was isolated from the WNV-FIN strain (P2 on Vero E6)
with the High Pure RNA isolation kit (Roche) according to the
instructions of the manufacturer. cDNA was synthesized using
random hexamer primers (Invitrogen) or a reverse primer
spanning the last 24 nucleotides of the 3’ UTR of published
WNV sequences, as well as Superscript III RT enzyme
(Invitrogen). Fifteen sets of primers spanning the complete
genome sequence of WNV were designed in conserved areas.
Primers were designed using the PrimerSelect module of
DNASTAR software (DNASTAR, Madison WI, USA). Primer
sequences are available from the authors upon request. cDNA
was amplified using PfuUltra II Fusion HS DNA Polymerase
(Stratagene) and DNA fragments were purified from gel and
sequenced directly in an ABI3130XL sequencer using the
same primers as used for PCR amplification. Sequences were
analysed using the SeqMan module of DNASTAR software.
Next generation sequencing (NGS)
Primers were designed for the E gene that allowed five
fragments of sizes between 200-400 nucleotides with about 50
nucleotides of overlap to be generated (Table S1). RT-PCR
was conducted using random primers (Invitrogen) and
Superscript III (Invitrogen), and DNA amplification was
performed using the specific primers and PFU polymerase
(Invitrogen). Fragments were gel-purified using QIAquick gel
extraction kit (Qiagen, Venlo, The Netherlands) and were
organized in libraries of equal concentration. Libraries were
created for each virus without DNA fragmentation (GS FLX
Titanium Rapid Library Preparation, Roche), emPCR
(Amplification Method Lib-L) and GS junior sequencing runs
were performed according to instructions of the manufacturer
(Roche). Amplicons were sequenced in a blinded fashion using
454 technology. Reads from the GS-FLX sequencing data
were sorted by bar code and aligned to reference sequences
using CLC Genomics software 4.6.1. Using the alignment, a
SNP table was made with a minimum coverage of 10 reads
and a minimum variant frequency of 1.0%. Raw nucleotide
sequences were filtered, aligned, trimmed and translated using
pre-specified criteria applied uniformly so that all the protein E
sequences used in the analyses spanned the exo-domain and
the transmembrane region.
Replication kinetics of WNV-FIN, Ita09 and 578/10
viruses
The replication kinetics of WNV-FIN, Ita09 and 578/10 were
studied in vitro by means of a one-step growth experiment
using a multiplicity of infection (MOI) of 5. N2a cells were
cultured overnight in 96-well flat bottom culture plates (105
cells/well) and virus was added. Viruses were allowed to
adsorb for one hour at 37 °C. Cells were subsequently washed
three times with serum-free medium to remove virus
inoculums, replenished with fresh medium and cultured at 37
°C for 24 hours. Culture supernatants were collected in
triplicate at time points 0 and 6 followed by sampling every 2
hours up to 24 hours, and were subsequently stored in -80 °C
until virus titer determination. Studies of replication kinetics
were conducted in parallel to eliminate any confounding effects
of host cell culture.
Several parameters were determined using the results of the
one-step growth experiment. The approximate eclipse period
was defined as the time point before infectious virus was
detected in the supernatant. The latent period (LT50) was
defined as the time point at which half the number of virus
progeny has been released into the environment and was
determined by use of curve fitting to the data points by least
squares (ordinary) fit. Replication rate (RR) is the slope
obtained by the linear regression of the natural logarithm (ln) of
the titer against time during the period of exponential growth.
Mouse infection and survival studies
Six-week old (age-matched) female C57BL/6 mice (Harlan
Laboratories B.V., Venray, The Netherlands) were inoculated
intraperitoneally (i.p.) with several doses of each three virus
strains (n=8 for each dose). Mice were euthanized by cervical
dislocation under isoflurane anaesthesia when they reached
humane end-points (immobility and paralysis), after which the
brain was immediately collected for further processing. At 14
days after infection, the end-point for the survival experiment
was reached and the survival rate was analyzed, and LD50 was
calculated according to the Reed & Muench [19] and the Probit
method [20]. Mice were maintained in specific pathogen-free
conditions, had a 12-hour day-night cycle and were fed ad
libitum. Serology studies were conducted using enzyme-linked
immunosorbent assay (ELISA).
Quantitation of virus in the brain
RNA copy numbers were quantified using a standard curve
of in vitro transcribed RNA of known quantities. Run-off
transcripts were generated from a plasmid containing the
sequence of the 3’ UTR of WNV-NY99. Plasmid was linearized
and run-off transcripts were generated using the Ambion®
MaxiScript T7/T3 kit (Invitrogen). The product was digested
with DNase to remove residual DNA and the reaction was
cleaned up using the Qiagen RNeasy Minikit (Qiagen). In vitro
transcribed RNA was diluted to a concentration at which DNA
was no longer detected. In order to quantify viral burden in the
brain, half the brain was weighed and homogenized using a
metal bead in 1 mL of DMEM containing antibiotics (100 U
penicillin, 100 µg/mL streptomycin). RNA copy numbers in the
brain homogenates were determined using qRT-PCR with the
Taqman® EZ RT-PCR kit (Applied Biosystems) and primers
and probe located on the 3’ UTR of WNV (Table S1). Infectious
titers in the brain were determined by titration of the brain
homogenates on Vero E6 cells and calculation of the TCID50.
Immunohistology
Sagittal brain and transverse spinal cord 4-µm thick paraffin
sections were processed for streptavidin-biotin-peroxidase
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immunohistochemistry and immunofluorescence of virus
nonstructural protein and cell-type markers. Sections were
deparaffinized in xylene, rehydrated in descending
concentrations of ethanol and incubated for 10 min in 3% H2O2
diluted in PBS to block endogenous peroxidase activity.
Antigen exposure was performed by incubation for 15 min at
121 °C in citrate buffer (0.01 M, pH 6.0). Sections were
incubated overnight at 4 °C with one of the following primary
antibodies: goat anti-WNV NS3 (1:100; R&D Systems,
Abingdon, UK), rabbit anti-human CD3 (T cell marker; 1:100;
Dako, Eindhoven, Netherlands), rabbit anti-GFAP (astrocyte
marker, 1:500; ZYMED, Breda, The Netherlands), and rabbit
anti-Iba1 (microglial marker, 1:500; WAKO, Ochten, The
Netherlands). For immunohistochemistry, primary antibodies
were detected with secondary goat anti-rabbit IgG-PO, rabbit
anti-goat IgG-PO (Dako) or biotinylated goat anti-polyvalent/
streptavidin peroxidase (Thermo Scientific, Etten-Leur, The
Netherlands) antibodies. Sections were counterstained with
Mayer’s hematoxylin and mounted with Kaiser’s glycerin-
gelatin and analyzed using a light microscope.
For double staining, immunofluorescence sections were
incubated with goat anti-WNV NS3, and either rabbit anti-Iba1,
rabbit anti-GFAP or rabbit anti-NeuN (neuronal marker, 1:500;
Millipore, Amsterdam, The Netherlands) was used. Secondary
antibodies directly conjugated to Alexa Fluor 488 (donkey anti-
goat) and 555 (donkey anti-rabbit) (Invitrogen) were used.
Nuclei were stained with DAPI. Fluorescence staining was
analyzed using a Zeiss LSM 700 confocal microscope.
Determination of inflammatory and cell death markers
by qRT-PCR
RNA was isolated from brain homogenates of infected mice
using the MagnaPure LC system according to the
manufacturer’s instructions. cDNA was synthesized using oligo
dT primer (Invitrogen) and Superscript III enzyme (Invitrogen)
according to the instructions of the manufacturer. Primers
specific for matrix metalloprotease (MMP)-3, MMP-9, tumour
necrosis factor (TNF)-α, neuronal pentraxin (Nptx)-1,-2 and
pentraxin-related protein (Ptx)-3 (Applied Biosystems) were
used in PCR amplification, and mRNA copy numbers were
quantified relative to β-actin using the following formula: (2-
quantity) *100000. Quantity was determined by subtracting the Ct
value of β-actin from the Ct value of the specific marker.
Statistical analysis
P-values equal to or less than 0.05 were considered to be
statistically significant. Survival curves were analyzed with the
Log-rank Test, differences between viral loads and differences
in expression of inflammatory and apoptotic markers were
assessed using the Mann-Whitney U test.
Results
The E protein of different WNV strains is not
significantly affected by in vitro culture
To determine whether generation of virus stocks, through
one extra passage on insect cells, resulted in changes in the
consensus sequence of the respective viruses, the E protein of
the different virus stocks was sequenced using the Sanger
method and sequences were compared to those deposited in
GenBank. All virus stocks were 99% identical to the sequences
of the low passage isolates deposited in GenBank (Figure S1).
There were no amino acid changes found in Ita09 and 578/10
compared to the sequences deposited in Genbank. The FIN
isolate, was compared to the highly similar sequence in
Genbank because FIN was not sequenced before. A
conservative amino acid substitution (histidine to tyrosine) was
found at position 371. The lineage 2 strain from Hungary
(578/10) differed by 20 amino acid substitutions from the
lineage 1 strains. We have determined the complete sequence
of the FIN isolate used in this study and the sequence was
deposited in GenBank (accession: KF234080).
Differences in amino acid sequence of closely related
strains WNV-FIN and Ita09
As the lineage 1 strains FIN and Ita09 are very closely
related and completely identical on a nucleotide level in terms
of the envelope, the complete genome of FIN was compared
with Ita09. The complete genome of the WNV-FIN strain
(KF234080) was 99.7% identical to the nucleotide sequence of
Ita09 (GU011992.2). Specifically, nine conservative nucleotide
substitutions were observed throughout the genome compared
to Ita09. In addition, three non-conservative amino acid
differences were observed in NS3, including the proline (Ita09)
to threonine (FIN) at position 249, a threonine (Ita09) to
isoleucine (FIN) change at position 267 and a histidine (Ita09)
to glutamine (FIN) change at position 488.
Dominant virus variants were recovered from viral
stocks and the brain of infected mice
Measuring the virulence of individual variants within a virus
stock may misrepresent the virulence of a quasispecies. Since
the virus population diversity is an important component of
virulence, we next characterized the population diversity in our
stocks using NGS (deep sequencing). Between 30-47 × 103
reads were obtained per sample from the virus stocks. Given
the sequence heterogeneity within protein E, the use of strain-
specific primer sets with degeneracy or located in conserved
regions resulted in efficient amplification. The reads generated
during sequencing were aligned using the reference sequences
deposited in GenBank. The viral RNA sequences recovered
from the brains yielded an average of 23-38 × 103 reads per
sample. Coverage of the amplicons was heterogenous and
ranged from 2,950 to 30,675 reads for RNA sequences
recovered from the viral stocks, and 1,079 to 28,362 reads for
viral RNA sequences recovered from the brain. After the
filtering steps, >99.7% of the original sequences were retained.
In FIN virus stock, 52.4% of the baseline viral population
consisted of the T form and 47.6% of the C form at reference
position 1176 (Figure 1), leading to a conservative amino acid
substitution (H371Y). Furthermore, at position 2118, 92.9% of
the variants contained the C form and 7.1% of the minor
mutations were of the T form. Several other low-frequency
mutations were found in the viral stock, ranging from 1% to 6%.
In the brain of FIN-infected animals, all the variants were in
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similar ratios, while the frequency of the minor variant at
position 2118 increased significantly by 26.1%. This variant,
C2118T, also resulted in a conservative amino acid substitution
(H685Y).
The baseline viral stock of Ita09 consisted of the 62.5% T
form and 37.5% of the C form at reference position 2058
(Figure 1). Several other minor variants were found, ranging
from 1.1% to 4.8%. For all the variants found in the viral stock,
only the predominant variants were detected in the brain of
infected animals, with the exception of the 2058 variant where
both mutations were found. The viral stock of 578/10 consisted
of only one variant at position 2270 with 96% of the T form and
4% of the C form (Figure 1). This variant was found at a similar
ratio in the brain. The results indicate that the predominant
variants in all the viral stocks were replicating in the brain of
infected animals and that minor variants were not preferentially
selected. The results from the NGS sequencing also confirmed
the consensus sequence that we acquired using the Sanger
method.
WNV-FIN, Ita09 and 578/10 have similar replication
kinetics in vitro
As the replicative capacity of a virus is considered a
surrogate marker for virulence, we decided to compare the
replication kinetics of the different WNV strains using a one-
step growth experiment. This approach assumes that virulent
strains produce more progeny within the host than the avirulent
ones, which in turn leads to higher viral densities and
consequently greater virulence levels. The one-step growth
curves of the different WNV strains are summarized in Figure
2A and Table 1. Infectious virus production by the three virus
strains began at approximately 14 hours post-infection.
Figure 1.  Virus variants recovered from the different WNV stocks and from the brains of infected mice.  Sequences of
glycoprotein E were obtained using Next Generation Sequencing (NGS) and aligned with reference sequences deposited in
GenBank. Variant frequencies are indicated by nucleotide substitution at a particular reference position.
doi: 10.1371/journal.pone.0074575.g001
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However, in order to obtain a more accurate estimate of the
latent period and facilitate comparisons between the strains,
we calculated the LT50, which is a mathematically more robust
determination of the latent period. As shown in Table 1, the RR
was found to be 1.69, 1.75 and 1.71 for FIN, Ita09 and 578/10,
respectively, indicating similar replication rates for the different
virus strains. The LT50 was calculated as 16.06, 13.44 and
16.09 hours for FIN, Ita09 and 578/10, respectively. This
indicates that Ita09 is released the earliest from the cell,
followed by FIN and 578/10. Furthermore, the burst size of
Ita09 was ten-fold higher compared to the two other strains.
Figure 2.  Infectious virus titers recovered from
supernatant over 24 hours after infection of N2a cells with
different WNV strains at different MOI.  N2a cells were
inoculated with WNV-FIN, Ita09 and 578/10 at an MOI of 5
TCID50/cell. Experiments were performed in triplicate and data
represent mean ± standard deviation.
doi: 10.1371/journal.pone.0074575.g002
Table 1. Analysis of the replication kinetics of WNV-FIN,
Ita09 and 578/10 on N2a cells at high (5) MOI over 24
hours.
Virus Eclipseperiod (h)
Latent
period (h) LT50 (h)
Burst size
(TCID50) RR
FIN 12 14 16,06 ± 0,02 101.1 1.69 ± 0.04
Ita09 12 14 13,44 ± 0,72 102.1 1.75 ± 0.05
578/10 12 14 16,09 ± 1,11 101.2 1.71 ± 0.02
Experiments were carried out in triplicate and values for LT50 and RR are indicated
as mean ± standard deviation. The LT50 was determined using curve fitting by
least squares (ordinary) fit and the replication rate (RR) is the slope obtained by
the linear regression of the natural logarithm (ln) of the titer against time during the
period of exponential growth.
LT: latent time, RR: replication rate.
doi: 10.1371/journal.pone.0074575.t001
Neuroinvasive properties of WNV-Ita09, FIN and 578/10
strains
As factors such as mortality rate, in vivo tropism, and
immune response to infection constitute important components
of virulence in the dynamic host environment, we first
determined the outcome of infection in 6-week old female
C57BL/6 mice following i.p. infection. Mice were infected with
three different doses of virus (104, 102 and 101 TCID50) and
differences in mortality rates were observed between the
respective WNV strains (Table 2). The cumulative mortality by
14 days after challenge was higher for 578/10 (91%) than FIN
(78%) and Ita09 (74%). However, comparison of the
cumulative survival curves of the mice infected with all doses of
the various strains revealed no statistically significant
differences (Figure 3B; P = 0.70). By contrast, significantly
more mortality was observed for Ita09 compared to FIN (P
<0.001) and 578/10 (P = 0.001) for the 104 TCID50 dose of virus
(Figure 3A). In addition, the ST50 for Ita09 was shorter (8.5
days) followed by 578/10 (11 days) and FIN (11 days).
The LD50 calculated using the Reed & Muench method is in
agreement with the probit method, indicating similar LD50
values for FIN and Ita09, while considerable lower values were
found for the 578/10 strain (Table 3).
High viral RNA load in brains of mice infected with Ita09
and 578/10 strains
We further investigated the viral burden in the brain of the
mice infected with the different strains of WNV and euthanized
when the humane end points were reached, within 14 days
post infection. RT-PCR analysis of brain homogenates
revealed high titers of viral RNA (105 -109) for all mice.
However, mean viral RNA copies were found to be significantly
higher in brains of mice infected with Ita09 and 578/10
compared to mice infected with FIN (P = 0.009 and P = 0.02,
respectively) (Figure 4A). However, in terms of infectious virus
titers (TCID50), no significant differences were observed in the
brains of these mice (P >0.05 for all) (Figure 4B).
Mice that did not develop signs of WNV neuroinvasive
disease by day 20 post infection (n=26) were considered
survivors of the infection. Infection was confirmed by the fact
that all these animals developed IgG antibodies to WNV (data
not shown). Viral RNA was detected in the brain of nine
survivors (Figure 4C). Specifically, four mice from the FIN
group (one from the 104, one from 102 and two from the 101
TCID50 group), and one mouse infected with 102 TCID50 of
Ita09. However, viral RNA titers were considerably lower
(101-105) in these mice compared to those that died from
infection. No significant differences were found in the number
of RNA copies in the brains of these mice compared to each
other (Figure 4C; P >0.05 for all). No viral RNA could be
detected in the blood of any of the animals that survived WNV
infection (data not shown), indicating that the detected RNA
was not spillover from blood.
Histopathology and immunohistochemistry
In order to assess if the viruses differ in their tropism for
particular regions of the brain, and compare the relative
damage caused by the different strains, we performed
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immunohistochemical staining with anti-WNV-NS3 polyclonal
antibody. WNV-NS3 positive cells occurred in brains and spinal
cords of all mice that developed neurological signs. Most
positive cells could be identified as neurons, with the antigen
being distributed in the cell body and proximal dendrites
(Figure 5A). Some positive cells showed features of
Figure 3.  Survival curves of mice inoculated
intraperitoneally with different WNV strains.  (A) Mice were
inoculated i.p. with 104 TCID50 WNV-FIN (n=8), Ita09 (n=7) and
578/10 (n=7). Significant differences in survival were observed
between FIN and Ita09 (P < 0.001), and Ita09 and 578/10 (P =
0.001). (B) Cumulative survival curves of mice inoculated i.p.
with doses of 101 TCID50, 102 TCID50, and 104 TCID50 of WNV-
FIN (n=23), Ita09 (n=23) and 578/10 (n=23). No statistical
significance was found between the cumulative survival curves
(P = 0.70). Mice were euthanized between days 6-14 upon
display of clinical signs of disease.
doi: 10.1371/journal.pone.0074575.g003
Figure 4.  Viral burden in the brains of mice infected with
WNV-FIN, Ita09 and 578/10.  Mice were euthanized within 6 to
14 days upon reaching humane endpoints and viral burden
was measured in terms of (A) RNA copies per gram of brain,
and (B) TCID50 per gram of brain. (C) Viral RNA copies per
gram of brain in mice infected with WNV-FIN, Ita09 and 578/10,
and euthanized on day 20 in the absence of clinical signs of
disease. * P <0.05, ** P <0.01.
doi: 10.1371/journal.pone.0074575.g004
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degenerative processes such as dystrophic neurites, small cell
body and pyknotic nuclei (Figure 5B). In addition, labeling was
associated with unidentifiable structures likely representing
neuronal debris. In order to confirm that positive cells were
neurons, we performed double-labeling immunofluorescence
with the neuronal marker NeuN (Figure 5C). Most positive cells
were positive for NeuN, while no WNV-NS3 positive cell was
positive for glial fibrillary acidic protein (GFAP, astrocytes) or
Iba1 (microglia), although in many occasions WNV positive
cells and debris-like structures were surrounded by Iba1
positive processes, pointing to an intimate relationship with
microglia cells (Figure 5D).
The extent of infection in the brain was determined in terms
of infected brain areas (Table S2). In general, positive neurons
occurred in all areas of the brain (Table S2) and the spinal
cord, although the regional distribution and relative density of
positive cells was highly variable between animals injected with
the same virus. For instance, animals infected with Ita09 virus
Table 2. Mortality of 6-week old i.p. infected C57BL/6 mice
using three different doses of WNV-FIN (n=23), Ita09
(n=23) and 578/10 (n=23).
WNV strain /
dose
First day
mortality
Last day
mortality
Median
day
mortality
Total
mortality
Mortality
(%)
Cumulative
mortality (%)
FIN
101 TCID50 9 11  4/8 50  
102 TCID50 10 12 11 6/7 85.7 78
104 TCID50 9 11  7/8 87.5  
Ita09
10-1
TCID50*
12 12  1/8 12.5  
101 TCID50 8 11  5/8 62.5  
102 TCID50 7 12 8.5 6/8 75 74
104 TCID50 7 9  7/7 100  
578/10
10-1
TCID50*
8 11  3/8 37.5  
101 TCID50 9 14  6/8 75  
102 TCID50 9 11 11 8/8 100 91
104 TCID50 8 12  7/7 100  
*. These groups were only used to calculate the LD50 and were not used for
determination of median day of mortality and cumulative mortality percentage.
doi: 10.1371/journal.pone.0074575.t002
Table 3. LD50 calculated with the Reed & Muench and the
Probit method of WNV-FIN (n=23), Ita09 (n=23) and 578/10
(n=23) i.p. infected C57BL/6 mice.
WNV strain LD50 (Reed & Muench) LD50 (Probit)
FIN 100.98 TCID50 100.75 TCID50
Ita09 100.43 TCID50 100.75 TCID50
578/10 10-0.42 TCID50 10-0.14 TCID50
doi: 10.1371/journal.pone.0074575.t003
Figure 5.  Histopathology of 6-week old C57BL/6 mice
infected with WNV-FIN, Ita09 and 578/10 and euthanized
upon reaching humane endpoints between days 6-14
p.i.  Representative picture of (A) Neurons in the hippocampus
of a mouse infected with Ita09, stained with anti-WNV NS3
antibody (objective 20×). Antigen is distributed in the cell body
(red arrow) and proximal dendrite (black arrow). Some of the
infected neurons appear to be in a healthy state with normal
nuclear, perikaryal and dendritic morphologies (red/black
arrow), while some uninfected neurons appear to be in a
moribund state (yellow arrow). (B) Neurons in the hippocampus
of a mouse infected with Ita09, stained with anti-WNV NS3
antibody (objective 20×). Antigen-expressing neurons appear
to be in a different state of health varying from healthy
appearance with normal nuclear, perikaryal and dendritic
morphologies (black arrow), to dying cells (red arrow). (C)
Double staining as seen by confocal microscopy (objective
20×) showing neurons (stained with NeuN antibody and Alexa
Fluor 555 conjugate; red) infected with Ita09 (stained with anti-
NS3 antibody and Alexa Fluor 488 conjugate; green). (D)
Double staining as seen by confocal microscopy (objective
40×) showing activated microglia (stained with anti-Iba1
antibody and Alexa Fluor 555 conjugate; red) engulfing
neurons infected with WNV-Ita09 (stained with anti-NS3
antibody and Alexa Fluor 488 conjugate; green). Nuclei are
stained with DAPI (blue). (E) Neo-cortical neurons in the brain
of a mouse infected with WNV-Ita09, stained with anti-WNV
NS3 antibody (objective 10×). (F) Neo-cortical neurons in the
brain of a mouse infected with WNV-FIN, stained with anti-
WNV NS3 antibody (red arrows; objective 10×) (G) Spinal cord
of a mouse infected with WNV-578/10, stained with anti-WNV
NS3 (objective 4×). Infection of motor neurons (red arrow),
anterior horn (orange arrow) and posterior horn (yellow arrow)
was observed. Insert shows infected motor neuron (objective
20×). (H) Purkinje cell in cerebellum of mouse infected with
Ita09 (red arrow), stained with anti-WNV NS3 antibody
(objective 20×). (I) Mild to moderate activation of astrocytes in
the cortex of a mouse infected with WNV-578/10, stained with
anti-GFAP (objective 20×). (J) Activation of microglia cells in
the cortex of the brain of a mouse infected with WNV-FIN,
stained with anti-Iba1 (objective 10×).
doi: 10.1371/journal.pone.0074575.g005
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showed highly sporadic, moderate amounts, or very frequent
NS3-positive neurons in the hippocampal CA1 area (Figure 5A
and B). A similar variability was also observed in other brain
areas, including the neocortex, striatum and cerebellar cortex
(Figure 5E and F), and there was no correlation between the
amount of positive cells in different brain areas in the same
mouse. Because of the large variability between animals
injected with the same viruses, it was difficult to determine
whether systematic differences occurred in the amount and
distribution of positive cells between animals injected with
different viruses. For instance, infection of Purkinje cells in the
cerebellum was observed in sections of some mice infected
with Ita09 (Figure 5H) and 578/10 but not in mice infected with
FIN. However, in view of the potential focal distribution of
infected cells, the question whether this difference holds true
for all Purkinje cells of FIN-injected mice would require the
systematic analysis of the entire cerebellum of all mice, which
is beyond the scope of this study. Nevertheless, based on the
analyses performed in this study, mice infected with Ita09 and
578/10 showed more positive cells than mice infected with FIN.
Furthermore, antigen distribution and quantity of positive
cells in the spinal cord was also highly variable, with WNV
positive cells occurring in both dorsal and ventral horns.
Although not systematically investigated, spinal motor neurons
in the ventral horn were infected more often than dorsal horn
cells, despite their relatively low abundance compared to other
spinal cord cells (Figure 5G).
Analysis of WNV-NS3 expression in the brains of mice that
did not develop clinical disease and that were killed at 20 days
post infection revealed no positive cells, which is consistent
Figure 6.  Relative number of RNA transcripts of markers in the brains of mice infected with WNV-FIN, Ita09 and
578/10.  Sick animals were euthanized within days 6-14 upon reaching humane endpoints or on day 20 post-infection in the
absence of clinical signs. Transcripts were compared with animals that survived WNV infection (day 20 p.i) and that were either
positive or negative for viral antigen in the brain. Mean is indicated by a cross and median by a line in the boxes. The box
represents the interquartile range. * P <0.05, ** P <0.01, *** P <0.001. Abbreviations: TNF = tumour necrosis factor; MMP = matrix
metalloproteinase; Nptx = neural pentraxin; Ptx = pentraxin.
doi: 10.1371/journal.pone.0074575.g006
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with the absence or low abundance of virus antigen in the
brains of these mice. Positive cells were also not found in the
spinal cord of these animals.
To determine whether the presence of virus-positive neurons
and neuronal debris correlated with microglia cell activation we
stained for Iba1, which is up-regulated in activated microglia
cells [21-24]. Increased Iba1 staining, as compared to control
mice, was observed in the nervous system of all mice with
virus-positive neurons (Figure 5J). In accord with the variability
in distribution and quantity of WNV-NS3 positive neurons,
changes in Iba1 staining was also variable between different
mice infected with the same virus or different viruses.
Remarkably, however, in some cases, areas with high levels of
WNV-NS3 positive cells and debris did not show a strong
increase in Iba1 positive cells, indicating that a high level of
virus-infected cells is not necessarily paralleled by high levels
of microglia cell activation. Astrocytosis (as demonstrated by
increased GFAP-staining) was seen in all animals and cases
ranged from mild to severe for all virus strains (Figure 5I).
Astrocytosis and microgliosis were also evident in the brains of
the survivor mice.
Finally, we analyzed infiltration of T-cells using anti-CD3
staining (Table S3). Perivascular cuffing by CD3-positive cells
was highly variable and was only evident in localized regions in
a subset of sections examined, consistent with the large
variability of infected areas. Infiltration of the neuropil by T cells
(CD3-positive cells) was mainly seen in animals infected with
Ita09 in the cerebrum and brainstem (~1 positive cell per high
power field [HPF]; objective 40×) and in some of the animals
infected with FIN or 578/10 (<1 cell per HPF in the brainstem).
Interestingly, infiltration of CD3-positive cells into the cerebrum
and brainstem were found in all mice that survived infection
with any of the WNV-strains. In comparison to the mice that
had died from infection, all mice that survived appeared to have
more CD3-positive cells in the brain. Taken together, the IHC
studies provide supportive evidence that Ita09 and 578/10 are
more virulent than FIN.
Response to WNV infection in brains of mice
To allow for quantitative comparison of the response to
infection with different strains of WNV, we performed qRT-PCR
using half brain homogenates (Figure 6). The survivor mice
were split into two groups based on presence or absence of
viral RNA in the brain. We chose for markers that have been
associated with viral encephalitis and neurodegenerative
diseases. The inflammatory marker TNF-α was increased in
the brains of mice infected with FIN (P = 0.002; P <0.0001),
Ita09 (P = 0.007; 0.007) and 578/10 (P = 0.006; 0.003)
compared to the survivors positive and negative for viral RNA
in the brain, respectively. One of the markers involved in the
breakdown of extracellular matrix, MMP-3, was significantly up-
regulated in the brains of mice infected with FIN (P = 0.004;
0.0009), Ita09 (P = 0.0007; 0.0007) and 578/10 (P = 0.003;
0.002) compared to convalescent mice with and without viral
RNA in the brain. In addition, MMP-3 transcript levels were
significantly higher in Ita09 compared to those infected with FIN
(P = 0.005). MMP-9 transcript was increased in mice infected
with FIN (P = 0.02) and 578/10 (P = 0.03) only when compared
to the convalescent mice positive for viral RNA in the brain.
Nptx-1 (a marker involved in apoptosis) was only up-regulated
in the brains of the survivor mice group with viral RNA in the
brain compared to the group without viral RNA (P = 0.05).
Nptx-2 and Ptx3, inflammatory markers involved in complement
activation and complement-mediated clearance of apoptotic
cells, were not significantly up-regulated in any of the
experimental groups. These data identify some inflammatory
markers significantly elevated during infection of the brain with
WNV, but none of the examined markers correlate with
virulence.
Discussion
In this study we have characterized the European WNV
strains FIN, Ita09 (both lineage 1) and 578/10 (lineage 2).
Neurovirulence of the three WNV strains were determined by
comparing in vitro replication kinetics, median day mortality,
cumulative mortality, LD50, concentration and distribution of
virus in the brain, and the response to infection in the brain.
Despite the fact that WNV has been circulating in Europe for
half a century, it is only in the more recent years that this virus
has caused considerable outbreaks in humans, horses and to a
much lesser extent in wild birds. This is in contrast to the
emergence of WNV in North America during which wild birds
were heavily affected and significant numbers of human
neuroinvasive disease cases with high mortality were reported.
It is possible that this increase in severity is a result of the
movement of the virus into areas with large immunologically
naïve populations that consist of a large proportion of elderly
and immunocompromised individuals [25]. However, it has also
been suggested that a more virulent strain of the virus was
introduced [26]. It is also hypothesized that the viruses
currently circulating in Europe differ in their virulence profile
compared to the North American strains.
There have been a number of explanations for why viruses
are virulent [27,28], and it is clear that virulence is an adaptive
process and that it is the result of the trade-offs between virus
transmissibility, virus pathogenic force, and recovery potential
of the host. In several models it has been shown that changes
in virulence are associated with changes in different aspects of
the biology of virus-host interaction, suggesting that virulence
of a given virus may be affected by a potentially large number
of factors (reviewed in [29-33]). Since no single general factor
exists that can be used to predict the relative virulence of
viruses, we investigated the virulence of European WNV
strains by considering a series of parameters. Even though it is
possible to investigate virulence by conducting a straight kinetic
analysis and examining viral spread in the brain over time, we
decided to use survival as an outcome of disease severity. This
is because disease can be a direct consequence of viral
burden, inflammatory response and injury and death of cells in
the CNS, and therefore an appropriate measure of virulence.
Following infection, WNV replicates to high levels during the
acute phase, after which the virus typically enters the brain and
causes meningo-encephalitis before the immune system is
able to control the infection. Our aim was to define the
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virulence profile of European WNV strains by measuring
different markers in vitro and in vivo.
First we determined the population structure (quasispecies)
in our virus stocks. We chose to characterize the stock rather
than the dominant variant in the stock that was used to infect
mice. It has been shown that viral quasispecies is more than
just a collection of mutants, but a group of interactive variants,
which together contribute to pathogenesis [34]. For instance, it
was found that the diversity of the quasispecies of Polio virus
correlated with enhanced pathogenesis in mice [34]. Ciota et
al. [35] have shown that the quasispecies in WNV populations
correspond to substantial phenotypic diversity that differed in
relative fitness in vitro. We have used NGS to determine the
population phenotype of our viral stocks, based on the
glycoprotein E gene. This gene was selected because it is the
principal receptor that determines tropism for neurons, contains
markers of virulence, and it harbors areas that allow monitoring
of virus evolution. One advantage of the NGS is the possibility
to detect minor variants. In this study, we found that only the
dominant variants from the stock were selected in the brain.
One important issue concerning the NGS is the ability to
distinguish between true variants and variants detected as a
result of errors introduced during PCR amplification and/or
sequencing. Therefore, within our department, we have
determined the error rate threshold specific for this platform.
We found that a threshold of 0.026% (manuscript in
preparation) is sufficient to exclude variants detected as a
result of errors. The technical cut-off value of 1% described in
this manuscript is therefore well above the error margin
attributed to reverse transcription, amplification and sequencing
errors. Furthermore, emergence of new variants was also
detected in the brain, which could have been a result of
mutations arising during the replication cycle. We did not
specifically study whether the population structure of our
strains contributed to virulence.
The infection cycle of WNV has not been studied extensively
in vitro, so we first addressed the dynamics of WNV infection in
vitro in neuronal cells. We found that only adherent cells could
be infected and infection of N2a cells in suspension was not
successful (data not shown). The reason for this phenomenon
is unknown, but may be related to receptor availability on
adherent cells. Currently, there is little known about the host
receptor for flaviviruses. The replication cycle of WNV can be
divided into three phases; (1) dispersal-diffusion-attachment
phase, (2) eclipse phase (begins with infection and ends when
the virus progeny matures inside the host), and (3) release
phase (the virus offspring are released from the infected cell).
The total number of progeny released in the supernatant is
termed the burst size. Examination of these three stages in
virus replication is useful, because the associated growth
parameters (eclipse period, latent period, exponential growth
rate, and burst) yield plausible hypotheses to account for
differences in virulence.
A study has shown that large clusters of matured virus of the
Sarafend strain appear at the plasma membrane, as well as in
vacuoles, at 10-12 hours post-infection [36]. This is in line with
our results where we determined the eclipse period to be at
approx. 12 hours p.i. The study further showed that maturation
of WNV at the plasma membrane, and therefore budding from
infected cells, is the dominant mode of maturation for this virus,
but that during the later stage of infection (from 12 hours p.i.)
the virus is also released via exocytosis, most likely due to
advanced cytopathic effects [36]. As a result, it may be difficult
to determine the precise time point of the burst size and we
have therefore additionally determined the LT50. Furthermore,
analyzing the RR may shed light on the potential of WNV
strains to overwhelm the target cells. Virions that are able to
overwhelm the system quickly will have an increased chance of
colonizing the remaining uninfected cells, an advantage
particularly important in vivo. We found that Ita09 replicates
faster as evidenced by the LT50 and release of up to ten-fold
more virus after the first replication cycle.
The increase in morbidity and case-fatality rates caused by
North American lineage 1 strains relative to lineage 2 strains
led to the hypothesis that lineage 1 strains are highly
pathogenic while lineage 2 strains that used to be endemic only
to Africa are of low virulence [4]. Conversely, recent outbreaks
in South Africa and Europe indicate that lineage 2 strains may
also cause severe disease [37]. This observation was also
supported by experimental studies in mice showing that
differences in virulent WNV strains did not correlate with the
phylogenetic lineage, source of isolate, geographic distribution,
passage level or year of isolation, and suggest instead that
pathogenicity is not genotype specific and that both lineage 1
and 2 are neurovirulent [38,39]. Our results indicate that all the
European strains studied are virulent in C57BL/6 mice and that
the lineage 1 strain (Ita09) and lineage 2 strain (578/10), which
share similar virulence profiles, are slightly more virulent than
FIN. Two lineage 1 viruses with 99.7% identity (FIN and Ita09)
were found to share a different virulence profile. These viruses
differed in terms of three non-conservative amino acids. One of
the substitutions present in the Ita09 strain, T249P, is a
mutation in the helicase domain of the NS3 protein and has
been associated with increased virulence in American crows
[40]. This mutation has been found in the more recent Italian
WNV isolates from 2008 (15803/08 and 15217/08), while the
Italy 1998-equine strain still has the threonine at this position
[41]. Interestingly, the 2010 Greek isolate also contains the
proline, and may be responsible for the increased virulence of
this strain compared to other strains from lineage 2 [10].
However, the virulence properties of this sole substitution in
outbred mice remains unclear, and its role in virulence in
humans on a population level is questionable. For instance, a
WNV strain isolated in 2007 from golden eagles in Spain
carrying a TP mutation did not have increased pathogenicity in
mice compared to other strains [42]. Similarly, the WNV-FIN
strain used in this study was isolated from a patient with
neuroinvasive disease. It is possible that the three amino acids
differences between Ita09 and FIN collectively reduced the
virulence of FIN.
Mice that had died as a result of infection with Ita09 and
578/10 were found to have a significantly higher number of
RNA copies in the brain compared to those infected with FIN.
Infectious virus titers, however, were not significantly different.
This discrepancy might be explained by the involvement of
immature virus particles, which may also play a role in the
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pathogenesis of WNV [43]. It is therefore possible that there
was a higher viral burden in the brains of mice infected with
Ita09 and 578/10 as a result of a larger amount of immature
virus particles, which may explain the higher virulence
observed for these virus strains.
The histopathologic findings observed in the brain and spinal
cord samples of the mice that succumbed to the infection were
pathognomonic, with moderate to severe infection observed in
mice infected with Ita09 and 578/10 strains. In agreement with
previous studies, WNV antigen was found in neurons in the
spinal cord, cortex, hippocampus and brainstem [15,44].
Interestingly, antigen of Ita09 and 578/10 was found also in the
Purkinje cells of the cerebellum. Infection of Purkinje cells by
North American strains of WNV has been demonstrated in
hamsters [45-47], birds [48,49], macaques [50] mice [51] and
humans [52]. This targeting of Purkinje cells of the cerebellum
has been shown to be a unique pathologic finding in WNV
encephalitis, unlike the encephalitides caused by other closely
related flaviviruses [48,53-57]. The higher frequency and
intensity of antigen staining in the central nervous system and
the higher mortality observed in the Ita09 and 578/10-infected
groups compared with the FIN–infected group (lineage 1),
suggest that these two strains are more virulent.
Even though some of the mice that survived infection were
positive for viral RNA, IHC staining did not demonstrate antigen
in the brain. The intensity of staining found using IHC did
roughly correlate with the amount of RNA found in the brain. As
RNA titers in the brain of the survivor mice were significantly
lower compared to mice that died from infection, it is possible
that these low titers, in addition to unsystematic sampling,
resulted in the absence of detection of positively stained cells
using IHC in brain samples of the survivor mice.
We have also measured the response to infection in the
brain as a virulence factor. Although astrocytosis and
microgliosis were observed in all mice that died from the
infection, we did not find evidence of infection of these cells. It
is believed that activated microglia and astrocytes contribute to
an excessive inflammatory response, which triggers a process
of secondary cell death or functional depression in structurally
normal areas distant from, but connected to the original sites
involved. We have found that MMP-3 transcript was
significantly elevated in all animals that developed severe
disease. MMPs are capable of degrading the tight junction
proteins of human brain microvascular endothelial cells,
thereby compromising the integrity of the blood-brain barrier.
Further studies are necessary to address the question of
whether MMP-3 is a virulence factor triggered by pathogenic
WNV strains.
To our knowledge, this is the first study to characterize
pathogenic properties of WNV strains circulating in Europe. We
have found that all three European strains of WNV are
neurovirulent in C57BL/6 mice; however, the data also suggest
that Ita09 and 578/10 show an increased virulence in
comparison to FIN. Studies are ongoing to determine the
virulence of these strains in European birds and in other
outbred animal models.
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